Administration of engineered soluble PDL1-Ig protein, which reduces the proliferation of T cells during transplantation, may be an alternative approach to reduce GvHD [46] although autoimmune complications will be an issue [47]. The gene discussed is CD274; the disease is graft versus host disease.